抗栓新模式——多学科协作Innovative antithrombotic therapy-Multi-disciplinary cooperation
李蕾,董淑杰,乔蕊,孙阿萍,葛洪霞,韩江莉,李宗师,韩金涛,贾子昌,杨航,王琨,张静,姚中强,王继军,于涛,马青变,傅瑜,张媛,刘书旺,赵荣生,范雯怡,高炜,唐熠达
摘要(Abstract)：
血栓栓塞性疾病的栓塞和出血风险并存已成为临床困境。疾病的多元化与药物更迭使抗栓治疗日益复杂和专业化，单一学科已不能胜任疑难病例的抗栓治疗。为更好地整合医疗资源，确保患者从规范化抗栓治疗中获益，北京大学第三医院突破学科间壁垒，组建了以心内科为主体，联合药剂科、检验科、神经内科、急诊科、消化科、心脏外科、呼吸科、介入血管外科、神经外科、风湿免疫科和血液科等12个科室参与的抗栓诊治专业团队，致力于制定合理的抗栓策略，着力解决临床血栓性疾病抗凝、抗血小板治疗中的关键问题，旨在探索一个“以心房颤动患者为中心”的多学科联合诊疗和精细化管理模式。
关键词(KeyWords)： 血栓栓塞性疾病;抗栓治疗;多学科协作
基金项目(Foundation): 国家自然科学基金项目（31700674）
作者(Author): 李蕾,董淑杰,乔蕊,孙阿萍,葛洪霞,韩江莉,李宗师,韩金涛,贾子昌,杨航,王琨,张静,姚中强,王继军,于涛,马青变,傅瑜,张媛,刘书旺,赵荣生,范雯怡,高炜,唐熠达
参考文献(References)：
- [1]《中国血栓性疾病防治指南》专家委员会.中国血栓性疾病防治指南[J].中华医学杂志，2018,98(36):2861-2888.
- [2] Tomaselli GF, Mahaf fey KW, Cuker A, et al. 2017 ACC Expert consensus decision pathway on management of bleeding in patients on oral anticoagulants:a report of the American College of Cardiology task force on expert consensus decision pathways[J]. J Am Coll Cardiol, 2017, 70(24):3042-3067.
- [3] Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fi brillation developed in collaboration with the European Association for CardioThoracic Surgery(EACTS):the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology(ESC)developed with the special contribution of the European Heart Rhythm Association(EHRA)of the ESC[J].Eur Heart J, 2021,42(5):373-498.
- [4] Stef fel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of nonvitamin K antagonist oral anticoagulants in patients with atrial fi brillation[J]. Eur Heart J, 2018, 39(16):1330-1393.
- [5] Rossini R, Tarantini G, Musumeci G, et al. A multidisciplinary approach on the perioperative antithrombotic management of patients with coronary stents undergoing surgery surgery after stenting 2[J]. JACC Cardiovasc Interv, 2018, 11(5):417-434.
- [6] Lim MY, Foster J, Rourk A, et al. Initial and long term impact of a multi-disciplinary task force in the diagnosis and management of heparin-induced thrombocytopenia[J]. J Thromb Thrombolysis, 2018, 45(1):130-134.
- [7] Spencer NH, Sardo LA, Cordell JP, et al. Structure and function of a perioperative anticoagulation management clinic[J]. Thrombosis Research, 2019, 182:167-174.
- [8] Ohgushi A, Nakayama N, Namiki A, et al. A retrospective evaluation of the impact of multi-disciplinary approach for improving the quality of anticoagulation therapy in ambulatory patients with non-valvular atrial fibrillation receiving warfarin[J]. Yakugaku Zasshi, 2019, 139(9):1177-1183.
- [9] Samama MM, Contant G, Spiro TE, et al. Laboratory assessment of rivaroxaban:a review[J]. Thromb J, 2013,11(1):11-12.
- [10] Samama MM, Contant G, Spiro TE, et al. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls[J].Thromb Haemost, 2012, 107(2):379-387.
- [11] Hongxia G, Yongjian W, Linhong N, et al. A retrospective study of coagulation abnormalities in patients receiving cefoperazone sodium and sulbactam sodium[J]. J Med Imaging Health Inform, 2015, 5(4):765-768.
- [12] Mueller RJ, Green D, Phair JP. Hypoprothrombinemia associated with cefoperazone therapy[J]. South Med J,1987, 80(11):1360-1362.